HealthCare Global (HCG) Enterprises, the chain of cancer care hospitals based in Bangalore, has partnered with Strand Life Sciences, a software and services development company, for life sciences research. The partnership will ensure standards in cancer treatment and risk predictions by using genomics-based diagnostics.

DNA sequencing

Genomics helps in determining the DNA sequencing of organisms and its genetic mapping. The one-sitting treatment, the result of which is processed within two weeks, will cost between ₹15,000 to ₹40,000.

Talking about the tie-up, BS Ajaikumar, Founder Chairman, HCB Enterprise, said: “We will now incorporate genomic testing which will be the future of cancer care.” This will help oncologists in clinical decisions and help our patients receive targeted individualised therapies that will improve diagnosis and prognosis of cancer,” he added. The genomics-based diagnostics offered by Strand Life Sciences will support physicians and patients to identify targeted therapies and treatment choices in the early stages of cancer. The genomic tests can also detect hereditary risk in the family members of cancer patients.

Talking about this partnership, Vijay Chandru, Chairman and CEO Strand Life Sciences said: “Strand is looking to expanding clinical genomics as a new paradigm for clinical decision support. The coming together of HCG, Triesta Sciences (unit of HCG) and Strand, will result in achieving a scale of adoption of genomic testing which is unprecedented even in the West.”

At present, the Strand-Triesta Centre for Cancer Genomics offers tests for breast, colon, lung and ovarian cancers. A 32-year-old cancer patient treated at HCG said the diagnosis gave him clarity on the therapies and treatment choices, the chances of cure, and the hereditary risk of cancer in his family members.

Related Topics
comment COMMENT NOW